950160 - Kolon Tissue Gene, Inc.

950160 Summary

Biopharma

Stock Price & Overview

₩17,100 +190 (+1.12%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩17,100 ≈ US$12 · Market cap ₩1.5tn (≈ $1.0bn)

950160 Financial Statements

Breakdown ₩ m	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	4	4	3	7	3	3	3	3	3	11	0
Cost of Revenue	3	3	3	1	3	3	2	2	1	0	0
Gross Profit	0	0	0	6	0	0	0	1	1	11	0
Selling, General & Administrative	16	17	16	19	41	36	38	31	37	15	8
Operating Income	-16	-16	-16	-13	-41	-35	-38	-30	-36	-3	-7
Finance Income	1	1	2	1	0	1	2	2	0	0	0
Finance Costs	122	10	0	0	0	1	1	1	1	0	0
Pretax Income	-135	-25	-13	-8	-41	-35	-42	-29	-37	-4	-8
Income Tax Expense	0	-0	0	-1	0	0	0	0	3	-2	0
Net Income	-135	-25	-13	-9	-41	-35	-42	-29	-40	-2	-8
Total Comprehensive Income	-136	-25	-13	-9	-42	-35	-42	-29	-40	-2	-8

Breakdown ₩ m	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	295	151	105	87	52	67	108	147	180	24	7
Current Assets	60	5	25	50	37	58	97	140	177	20	6
Cash & Cash Equivalents	47	1	21	33	33	17	39	18	27	19	6
Inventories	0	0	0	0	0	0	0	1	1	0	0
Trade Receivables	0	0	1	0	0	1	3	1	1	0	0
Non-current Assets	235	146	80	37	15	9	10	7	3	4	1
Property, Plant & Equipment	1	1	1	2	2	2	3	1	1	1	1
Intangible Assets	217	136	68	25	5	0	0	5	1	0	0
Total Liabilities	251	52	15	15	19	23	27	24	30	17	8
Current Liabilities	248	48	11	9	14	14	12	12	12	3	0
Non-current Liabilities	3	4	4	5	6	9	15	13	18	15	7
Total Equity	45	99	89	72	33	44	81	123	149	7	-1
Share Capital	0	0	0	0	0	0	0	0	0	0	0
Retained Earnings	-436	-300	-276	-262	-254	-212	-176	-133	-104	-64	-62

Breakdown ₩ m	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	-17	-15	-18	-21	-35	-32	-38	-31	-34	-3	-7
Cash from Investing Activities	-93	-57	-22	-31	29	16	64	24	-149	-0	-0
Purchase of Property, Plant & Equipment	1	0	0	0	0	1	2	0	0	0	0
Cash from Financing Activities	156	51	29	52	21	-6	-5	-2	190	17	7
Net Change in Cash	47	-21	-12	0	16	-22	21	-8	7	14	0

Breakdown ₩ m	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	1	1	1	1	1	1	1	2	1	1
Cost of Revenue	0	1	1	1	1	1	0	1	1	1
Gross Profit	0	0	0	0	0	0	0	0	0	0
Selling, General & Administrative	5	4	6	3	4	4	5	4	4	3
Operating Income	-5	-4	-6	-3	-4	-4	-5	-4	-4	-3
Finance Income	1	0	1	0	0	0	0	0	0	0
Finance Costs	-32	67	84	3	35	0	10	0	0	0
Pretax Income	33	-68	-87	-4	-40	-4	-14	-4	-4	-3
Income Tax Expense	—	0	0	0	0	0	0	0	-0	0
Net Income	33	-68	-87	-4	-40	-4	-14	-4	-4	-3
Total Comprehensive Income	33	-68	-87	-4	-40	-4	-14	-4	-4	-3

Breakdown ₩ m	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	333	337	295	290	205	211	151	146	132	105
Current Assets	66	84	60	92	24	42	5	24	28	12
Cash & Cash Equivalents	44	63	47	72	10	36	1	22	25	9
Inventories	0	0	0	0	0	0	0	0	0	0
Trade Receivables	0	0	0	0	0	0	0	0	0	0
Non-current Assets	267	253	235	198	181	169	146	122	104	93
Property, Plant & Equipment	1	1	1	2	1	1	1	1	1	1
Intangible Assets	248	235	217	188	171	159	136	111	93	80
Total Liabilities	200	255	251	159	120	86	52	33	15	18
Current Liabilities	198	252	248	156	116	82	48	30	11	14
Non-current Liabilities	3	3	3	3	3	4	4	4	4	4
Total Equity	132	82	45	131	85	125	99	113	117	86
Share Capital	0	0	0	0	0	0	0	0	0	0
Retained Earnings	-471	-504	-436	-349	-345	-304	-300	-287	-282	-278

Breakdown ₩ m	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	-1	-4	-3	-4	3	-13	-3	-4	-4	-4
Cash from Investing Activities	-18	-20	-21	-22	-30	-20	-18	-17	-13	-8
Purchase of Property, Plant & Equipment	0	0	0	0	0	0	0	0	0	0
Cash from Financing Activities	-0	40	-0	87	0	69	-0	17	34	-0
Net Change in Cash	-19	15	-24	62	-26	36	-21	-4	16	-12

Separate / parent-only (OFS) — this company files no consolidated statements, from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

950160 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	0.0	-2.5%	-20.9%	+3.8%	+29.5%
Operating income	-0.0	—	—	—	—
Net income	-0.1	—	—	—	—
EPS	₩-2	—	—	—	—
Operating cash flow	-0.0	—	—	—	—
Shareholders' equity	0.0	-55.0%	-14.8%	+0.2%	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

950160 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	13.3%	11.7%	11.1%	81.3%	10.9%	10.6%
Operating margin	-432.7%	-433.6%	-553.3%	-172.4%	-1,171.7%	-1,168.7%
Net margin	-3,733.3%	-666.2%	-464.8%	-117.8%	-1,183.3%	-1,175.2%
Return on equity	-188.2%	-26.3%	-16.4%	-16.5%	-107.8%	-56.6%
Return on assets	-60.6%	-19.4%	-13.8%	-12.4%	-69.7%	-40.6%
Operating cash flow / revenue	-465.5%	-403.1%	-650.5%	-283.2%	-999.7%	-1,072.2%
Capex / revenue	23.2%	2.5%	7.0%	0.7%	13.7%	23.3%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 950160

Symbol	Last Price
140410Mezzion Pharma Co., Ltd.	₩65,000 +0.0%
068760Celltrion Pharm, Inc.	₩40,850 +0.0%
007390Naturecell Co., Ltd.	₩23,950 +0.2%
006280GC Biopharma Corp.	₩127,600 +0.5%
039200Oscotec, Inc.	₩36,600 +1.9%
069620Daewoong Pharma	₩116,100 +1.1%
290650L & C BIO Co., Ltd.	₩47,900 -1.4%
127120JS Link	₩33,600 +12.4%
475830Orum Therapeutics, Inc.	₩55,900 +2.6%
195940HK inno.N Corporation	₩42,050 +0.7%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.